In the latest trading session,, 1.51 million Pacific Biosciences of California Inc (NASDAQ:PACB) shares changed hands as the company’s beta touched 2.10. With the company’s most recent per share price at $1.01 changed hands at -$0.02 or -1.93% at last look, the market valuation stands at $304.59M. PACB’s current price is a discount, trading about -169.31% off its 52-week high of $2.72. The share price had its 52-week low at $0.95, which suggests the last value was 5.94% up since then.
Analysts gave the Pacific Biosciences of California Inc (PACB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.27. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended PACB as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB was in red as seen in intraday trades today. With action -7.73%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -44.54%, with the 5-day performance at -7.73% in the red. However, in the 30-day time frame, Pacific Biosciences of California Inc (NASDAQ:PACB) is -13.25% down.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 66.33% from its recent market value. According to analyst projections, PACB’s forecast low is 2 with 4 as the target high. To hit the forecast high, the stock’s price needs a -296.04% plunge from its current level, while the stock would need to soar -98.02% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.55%. The 2025 estimates are for Pacific Biosciences of California Inc earnings to decrease by -8.04%, but the outlook for the next 5-year period is at 27.92% per year.
PACB Dividends
Pacific Biosciences of California Inc is expected to release its next quarterly earnings report in June.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.5449% or 26.0 million shares worth $35.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . With 21.4 shares estimated at $21.72 million under it, the former controlled 7.13% of total outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held about 3.77% of the shares, roughly 11.32 shares worth around $11.49 million.
